ENAMS: Energy optimization algorithm for mobile wireless sensor networks using evolutionary computation and swarm intelligence.

Although traditionally Wireless Sensor Network (WSNs) have been regarded as static sensor arrays used mainly for environmental monitoring, recently, its applications have undergone a paradigm shift from static to more dynamic environments, where nodes are attached to moving objects, people or animals. Applications that use WSNs in motion are broad, ranging from transport and logistics to animal monitoring, health care and military. These application domains have a number of characteristics that challenge the algorithmic design of WSNs. Firstly, mobility has a negative effect on the quality of the wireless communication and the performance of networking protocols. Nevertheless, it has been shown that mobility can enhance the functionality of the network by exploiting the movement patterns of mobile objects. Secondly, the heterogeneity of devices in a WSN has to be taken into account for increasing the network performance and lifetime. Thirdly, the WSN services should ideally assist the user in an unobtrusive and transparent way. Fourthly, energy-efficiency and scalability are of primary importance to prevent the network performance degradation. This thesis contributes toward the design of a new hybrid optimization algorithm; ENAMS (Energy optimizatioN Algorithm for Mobile Sensor networks) which is based on the Evolutionary Computation and Swarm Intelligence to increase the life time of mobile wireless sensor networks. The presented algorithm is suitable for large scale mobile sensor networks and provides a robust and energy- efficient communication mechanism by dividing the sensor-nodes into clusters, where the number of clusters is not predefined and the sensors within each cluster are not necessary to be distributed in the same density. The presented algorithm enables the sensor nodes to move as swarms within the search space while keeping optimum distances between the sensors. To verify the objectives of the proposed algorithm, the LEGO-NXT MIND-STORMS robots are used to act as particles in a moving swarm keeping the optimum distances while tracking each other within the permitted distance range in the search space

Comparative study of Arduino Types and Raspberry Pi with Programming Languages

The world is developing at an amazing speed through modern technologies to control things and microcontrollers have become a preoccupation of most developers of remote and proximity control devices in various industrial, household, and educational sectors, so it is necessary to study them in-depth and know the differences between Arduino and Raspberry in terms of hardware and software so that the developer is aware of what they can use it to build his project. Both Arduino and Raspberry are microcontrollers, but the first works without the need to connect to a computer, and works through an open source program as it is a single board and deals with a simple program every time and can connect to the Internet, while Raspberry connects to a computer via USB It deals with the language of Linux and Ruby and can perform mathematical and arithmetic operations and encrypt Bitcoin currencies, for these reasons, all these concepts will be explained in this paper, and that any technician or programmer can choose the best electronic parts Arduino or Raspberry in order to get the project done better

Alarm Emergency in Virtual Small City

In this paper a control  AT89C51 microcontroller system was proposed to used in the design of alarm emergency in virtual small city. The proposed system includes personal computer (PC), monitoring, control circuit which has a microcontroller. When the accident accrued, the system sends alarm from any anywhere compromised with a number of the street to the emergency office and emergency alarms bureau official received by the monitoring that appear on the map and this point sends warning

Effect of coccidioidomycosis prophylaxis in selecting non-Candida albicans species amongst solid organ transplant recipients in Arizona

Background: Invasive candidiasis carries an increased risk of morbidity and mortality. The rates of non-albicans Candida species (NAC) infections are on the rise secondary to frequent azole antifungal use. NAC incidence and risk amongst solid organ transplant (SOT) recipients in Arizona receiving prolonged azole course for coccidioidomycosis prophylaxis have not been well elucidated. Methods: We retrospectively evaluated SOT recipients hospitalised between 2017 and 2021 with a positive Candida spp. culture. Results: There were 66 SOT recipients with 74 hospitalisations and 79 Candida spp. isolates. The median age was 59 (IQR 45–66), 68% were male, 58% were non-Hispanic White, and the most common SOT 38/74 (51%) was a liver transplant. Median time from transplant to the identification of any NAC (infection or colonisation) was significantly shorter, 8 months (IQR 3–78) vs 128 months (IQR 10–282) for Candida albicans isolates, p =.03. Prior use of azoles was significantly higher in NAC-associated post-transplant colonisation and invasive disease hospitalisations (83%) than in those with C. albicans (17%), p <.001. There were 59 hospitalisations with invasive disease, with the majority having NAC isolates of 49 (83%). Conclusion: The universal azole prophylaxis has reduced the incidence of coccidioidomycosis complications amongst SOT recipients in Arizona; however, there is an increased risk of developing NAC colonisation and infections, which can complicate the care of the SOT recipients with invasive candidiasis. Future studies are needed to investigate methods of reducing the risk of NAC infections whilst preventing coccidioidomycosis amongst SOT recipients.12 month embargo; first published: 19 November 2022This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature

Background: The genus Blastobotrys consists of at least 20 species. Disease in humans has been reported with B adeninivorans, B raffinosifermentans, B proliferans and B serpentis, mostly in immunocompromised patients and those with cystic fibrosis. Objective: We report a lung infection secondary to B raffinosifermentans in a cystic fibrosis patient successfully treated with isavuconazole and review the literature of invasive infections caused this genus. We also evaluated clinical isolates in our laboratory for species identification and antifungal susceptibility. Methods: Phylogenetic analysis was performed on a collection of 22 Blastobotrys isolates in our reference laboratory, and antifungal susceptibility patterns were determined for nine clinically available antifungals against 19 of these isolates. Results: By phylogenetic analysis, 21 of the 22 isolates in our collection were identified as B raffinosifermentans and only 1 as B adeninivorans. Most were cultured from the respiratory tract, although others were recovered from other sources, including CSF and blood. Isavuconazole, caspofungin and micafungin demonstrated the most potent in vitro activity, followed by amphotericin B. In contrast, fluconazole demonstrated poor activity. The patient in this case responded to isavuconazole treatment for breakthrough infection due to B raffinosifermentans that was cultured from pleural fluid while on posaconazole prophylaxis post–bilateral lung transplantation for cystic fibrosis. Conclusions: Blastobotrys species are rare causes of infections in humans and primarily occur in immunocompromised hosts. In our collection, the majority of isolates were identified as B raffinosifermentans. To our knowledge, this is the first report of successful treatment of such an infection with isavuconazole. © 2021 Wiley-VCH GmbH12 month embargo; first published online 8 February 2021This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

The Utility of (1&rarr;3)-&beta;-D-Glucan Testing in the Diagnosis of Coccidioidomycosis in Hospitalized Immunocompromised Patients

Coccidioidomycosis is a fungal infection endemic to the Southwestern United States which is associated with high morbidity and mortality in immunocompromised hosts. Serology is the main diagnostic tool, although less sensitive among immunocompromised hosts. (1&rarr;3)-&beta;-D-glucan (BDG) is a non-specific fungal diagnostic test that may identify suspected coccidioidomycosis and other invasive fungal infections. We retrospectively investigated the utility of BDG between 2017 and 2021 in immunocompromised hosts with positive Coccidioides spp. cultures at our institutions. During the study period, there were 368 patients with positive cultures for Coccidioides spp.; among those, 28 patients were immunocompromised hosts, had both Coccidioides serology and BDG results available, and met other inclusion and exclusion criteria. Half of the patients had positive Coccidioides serology, and 57% had a positive BDG &ge; 80 pg/mL. Twenty-three (82%) had at least one positive test during their hospitalization. Among immunocompromised hosts with suspicion for coccidioidomycosis, the combination of Coccidioides serology and BDG can be useful in the initial work up and the timely administration of appropriate antifungal therapy. However, both tests failed to diagnose many cases, underscoring the need for better diagnostic techniques for identifying coccidioidomycosis in this population

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthcare System (a large not-for-profit organization) between 4/5/2022 and 8/1/2022 and included 19,778 Coronavirus disease-19 (COVID-19) positive (by PCR or direct antigen testing) patients who were selected from Cerner-Electronic Health Record after the exclusions criteria were met. The study index date for cohort was determined as the date of BEB MAb administration or the date of the first positive COVID-19 testing. The cohort consist of COVID-19 infected patients who received BEB MAb (N = 1,091) compared to propensity score (PS) matched control (N = 1,091). The primary composite outcome was the incidence of 30-day all-cause hospitalization and/or mortality. All statistical analyses were conducted on the paired (matched) dataset. For the primary composite outcome, the event counts and percentages were reported. Ninety-five percent Clopper-Pearson confidence intervals for percentages were computed. The study cohorts were 1:1 propensity matched without replacement across 26 covariates using an optimal matching algorithm that minimizes the sum of absolute pairwise distance across the matched sample after fitting and using logistic regression as the distance function. The pairs were matched exactly on patient vaccination status, BMI group, age group and diabetes status. Compared to the PS matched control group (2.6%; 95% confidence interval [CI]: 1.7%, 3.7%), BEB MAb use (2.2%; 95% CI: 1.4%, 3.3%) did not significantly reduce the incidence of the primary outcome (p = 0.67). In the subgroup analysis, we observed similar no-difference trends regarding the primary outcomes for the propensity rematched BEB MAb treated and untreated groups, stratified by patient vaccination status, age (<65 years or ≥65), and immunocompromised status (patients with HIV/AIDS or solid organ transplants or malignancy including lymphoproliferative disorder). The number needed to treat (1/0.026-0.022) with BEB MAb was 250 to avoid one hospitalization and/or death over 30 days. The BEB MAb use lacked efficacy in patients with SARS-CoV-2 Omicron subvariants (mainly BA.2, BA.2.12.1, and BA.5) in the Banner Healthcare System in the Southwestern United States

The primary composite outcome between the propensity matched Bebtelovimab (BEB) monoclonal antibody (MAb) and untreated control groups.

The primary composite outcome between the propensity matched Bebtelovimab (BEB) monoclonal antibody (MAb) and untreated control groups.</p